Good news for Migraine sufferers ...
"Enzogenol is a highly effective natural product for the successful treatment of migraine. The data suggests that Enzogenol may be beneficial in the treatment of migraine by reducing headache frequency, longevity and severity".
A recent Enzogenol study found that after just 3 months supplementation, Enzogenol reduced the debilitating effects that migraines have. Patients were assessed using the Migraine Disability Assessment Score (MIDAS) for the 3 month period prior to supplementation and for the three months of supplementation.
The frequency of migraine attacks was recorded as number of headaches for the 3 month period prior to supplementation and during the 3 month supplementation period. Similarly, the severity of the attacks was recorded as a symptom score on a scale from 0 to 10 for increasing severity.
How Do You Measure a Migraine
MIDAS assesses the overall impact that the migraine attacks have on a patients life. This includes: days off work or school missed, days where productivity was half or less, days where work was not done, days with household productivity half or less, and days where social activities were missed.
The Study
The study was carried out with migraine sufferers with a long term history of migraine and who had previously failed to respond to various pharmacological approaches, sufferers were given high dose Enzogenol for 3 months. No adverse events were noticed in this study. Taking high doses of Enzogenol was very well tolerated. The results showed that Enzogenol supplementation was associated with beneficial effects on parameters of migraine attack frequency and severity.
Results
The study showed that Enzogenol was effective in reducing the debilitating impact of migraines, as measured by MIDAS, by over 50%. The frequency of migraine attacks was reduced by approximately 41% and the severity decreased by approximately 26%.
There was a significant mean improvement in MIDAS score of 50.6% for the 3-month treatment period compared with the 3 months prior to baseline. The treatment was also associated with significant reductions in number of headache days and headache severity score. Mean number of headache days was reduced from 44.4 days at baseline to 26.0 days after 3 months therapy and mean headache severity was reduced from 7.5 of 10 to 5.5.
Conclusion
The study found that the frequency of attacks was markedly reduced. The severity of the migraines was also found to be reduced. This data suggests that the Enzogenol therapy used in this study may be beneficial in the treatment of migraine by reducing headache frequency and severity.
